The results were compared with traditional imaging methods (bone scan, CT, MRI) in the overlapping subset of patients with both examinations to assess changes in TNM staging and treatment plans.<h4>Results</h4>After PSMA PET/CT, TNM staging changed in 48 patients (38.40%), particularly in the primary prostate cancer and pre-radical surgery groups regarding regional lymph node detection (P = 0.007, P = 0.040). The gene discussed is FOLH1; the disease is prostate cancer.